HCL PHARMA
ActiveHCL PHARMA has been active since 2016 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €57k and a net result of €36k. Equity is growing by ~11.4% per year across the filed fiscal years. Its solvency ranks better than 21% of 10310 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 1.1% (low).
Checked score
Score 2025
61
/ 100
Healthy
The score weighs solvency, liquidity and profitability. Bankruptcy probability contributes 35%. Every signal that weighs is under Signals.
Axes · tick = 2024
Profitability78▲+8
Solvency36▼-14
Growth78▲+26
Track record100
Bankruptcy probability, 12 months
1.1%
Low
0%0.5%1.5%4%10%≥ 25%
Credit up to €3k at 30 days acceptable
Liquidity short (current ratio 0.75 against 0.46 in 2024; short-term debt: 16.3% and cash: 8.8% of total assets), and 88.6% of the assets are financed with debt.
Credit advice for your own amount and term
Signals
Eight signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 47
Relative position
BE, all sectors
reference
Sector 47
higher
← fewer bankruptcies
more bankruptcies →
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2025Solvency, return and age of the figures
Solvency
11.4%
Return on assets
7.2%
Age of the figures
9 mo
raises risk · Weak solvency vs sector
Solvency (equity / total assets) is in the sector's weakest quartile: better than 21% of 10310 sector peers (2025).
NBB · sector comparisonPosition among 10310 sector peers
Solvency
better than 21%
← weakest
strongest →
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 29-07-2026, 2 days ahead of the deadline.
NBB · 9 filingsDeviation from the deadline
2025
2 d early
2024
14 d early
2023
30 d late
2022
18 d early
2021
26 d early
2020
21 d early
2019
21 d early
← before the deadline
after the deadline →
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven monthsPosition in the running window
19-09-2026 today31-12-2026 close31-07-2027 deadline
Financials · fiscal year 2025, abbreviated schema
Turnover
€0
EBIT margin
Not included in this filing
Net result
€36k▲ 514%
2024 · €6k
2018: €21k
2019: €27k
2020: €21k
2021: €15k
2022: €4k
2023: €13k
2024: €6k
2018 → 2025
Working capital
€-21k▲ 40.8%
2024 · €-35k
2018: €12k
2019: €28k
2020: €19k
2021: €-3k
2022: €-29k
2023: €-35k
2024: €-35k
2018 → 2025
Multi-year overview
Every figure with its change against the year before
▲ rise
▼ fall
Line20212022202320242025Trend
Equity€97k-€101k▲ 3.9%€115k▲ 13.2%€121k▲ 5.2%€57k▼ 52.6%
Operating result€25k-€12k▼ 53.2%€23k▲ 94.6%€13k▼ 42.2%€53k▲ 297%
Net result€15k-€4k▼ 75.5%€13k▲ 254%€6k▼ 55.5%€36k▲ 514%
Result per fiscal year
Operating resultNet result
The operating result recovers in 2025; 2025 is 297% above 2024 and is the highest result in the available series.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €502k
Fixed assets
€441k▼ 3.3%
Current assets
€61k▲ 105%
Equity and liabilities €502k
Equity
€57k▼ 52.6%
Debt
€445k▲ 21.8%
The debt ratio rises from 75.2% to 88.6%. Equity is lower and debt is higher.
Key figures and ratios
EBITDA
€81k▲
2024 · €40k
Cash flow
€64k▲
2024 · €32k
Solvency
11.4%▼
2024 · 24.8%
Current ratio
0.75▲
2024 · 0.46
Quick ratio
0.75▲
2024 · 0.46
Debt / equity
7.79▲
2024 · 3.03
ROE
63.8%▲
2024 · 4.9%
ROA
7.2%▲
2024 · 1.2%
Interest coverage
14.11▲
2024 · 6.44
Debt
€445k▲
2024 · €366k
Debt ≤ 1 year
€82k▲
2024 · €65k
Debt > 1 year
€363k▲
2024 · €300k
Income taxes
€11k▲
2024 · €2k
Green means a favourable move, even when the figure itself falls: as with debt or debt / equity.
Filed annual accounts
As filed with the NBB · 2025 against 2024
Balance sheet
Code20242025
Assets
Total assets20/58€486k€502k▲
Fixed assets21/28€456k€441k▼
Tangible fixed assets22/27€296k€280k▼
Land and buildings22€286k€268k▼
Plant, machinery and equipment23€2k€1k▼
Furniture and vehicles24€5k€9k▲
Other tangible fixed assets26€3k€2k▼
Financial fixed assets28€161k€161k=
Current assets29/58€30k€61k▲
Amounts receivable within one year40/41€16k€15k▼
Trade receivables40€14k€13k▼
Other amounts receivable41€2k€1k▼
Cash at bank and in hand54/58€13k€44k▲
Deferred charges and accrued income490/1€1k€2k▲
Equity and liabilities
Total equity and liabilities10/49€486k€502k▲
Equity10/15€121k€57k▼
Contributions10/11€12k€19k▲
Reserves13€1k€1k=
Non-distributable reserves130/1€1k€1k=
Reserves not available under the articles1311€1k€1k=
Tax-exempt reserves132€272€272=
Profit (loss) carried forward14€107k€37k▼
Amounts payable17/49€366k€445k▲
Amounts payable after more than one year17€300k€363k▲
Financial debts170/4€238k€209k▼
Other amounts payable178/9€62k€154k▲
Amounts payable within one year42/48€65k€82k▲
Current portion of amounts payable after more than one year42€28k€29k▲
Trade debts44€3k€4k▲
Suppliers440/4€3k€4k▲
Taxes, remuneration and social security45€6k€20k▲
Taxes450/3€5k€19k▲
Remuneration and social security454/9€115€1k▲
Other amounts payable47/48€28k€30k▲
Accrued charges and deferred income492/3€650€0▼
Income statement
Code20242025
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€26k€28k▲
Other operating charges640/8€4k€2k▼
Gross operating margin9900€44k€83k▲
Operating profit (loss)9901€13k€53k▲
Financial income75/76B€301€0▼
Recurring financial income75€301€0▼
Financial charges65/66B€6k€6k▼
Recurring financial charges65€6k€6k▼
Profit (loss) for the period before taxes9903€8k€47k▲
Income taxes67/77€2k€11k▲
Profit (loss) for the period9904€6k€36k▲
Profit (loss) for the period to be appropriated9905€6k€36k▲
Appropriation of the result
Profit (loss) to be appropriated9906€107k€143k▲
Profit (loss) brought forward from the previous period14P€101k€107k▲
Profit to be distributed694/7-€106k
Return on contributions (dividend)694-€106k
The notes to these accounts (20 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
29-07
NBB filing
Annual accounts filed
fiscal year 2025 · abbreviated schema
2025
31-12
Financial
Highest result since 2018net €36k ▲514%
Operating result €53k, net result €36k, both a record.
17-07
NBB filing
Annual accounts filed
fiscal year 2024 · full schema
2024
30-08
NBB filing
Annual accounts filed
fiscal year 2023 · full schema · 30 days late
2023
13-07
NBB filing
Annual accounts filed
fiscal year 2022 · full schema
2022
31-12
Financial
Weakest financial yearnet €4k ▼75.5%
Net result drops to €4k, the lowest in the series; recovery starts the following year.
31-12
Financial
Equity above €100kEq €101k ▲3.9%
5 profitable years in a row build equity to €101k.
05-07
NBB filing
Annual accounts filed
fiscal year 2021 · full schema
2021
10-07
NBB filing
Annual accounts filed
fiscal year 2020 · full schema
2020
10-07
NBB filing
Annual accounts filed
fiscal year 2019 · micro schema
2019
04-07
NBB filing
Annual accounts filed
fiscal year 2018 · micro schema
2018
03-07
NBB filing
Annual accounts filed
fiscal year 2017 · micro schema
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Directors · office · real estate
Directors
2 acts for this company are in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Walcourt · 2 establishment units since 2016
Cannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Rue du Jardinet(Wal) 65650 WalcourtGround area
764 m²
Building footprint
336 m²
2 parcels, Wallonia. Linked by address, not a title deed.
2 establishment units
HCL PHARMA
since 20162.253.479.056
HCL PHARMA
since 20162.253.479.155
2 parcels
Wallonia
2
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 93088A0055/00W006 | Wallonia | 632 m² | 1 · 263 m² | - |
| 93088C0195/00B000 | Wallonia | 132 m² | 1 · 72 m² | - |
Linked by address, not proof of ownership
Methodology
via registered seat: 1 · via establishment units: 1
2 of 2 parcels with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Similar companies · same sector, comparable size
PHARMACIE MON ANGE
BE 0878.040.238
Etterbeek · Eq €57k
KameleonPharma
BE 0666.453.742
Wellen · Eq €57k
Benisa BV
BE 0731.796.704
Dilsen-Stokkem · Eq €57k
EVRAS
BE 0417.723.174
Frameries · Eq €57k
EL MANAGEMENT
BE 1003.039.287
Waremme · Eq €57k
Of 5,222 companies in sector 47730 we hold annual accounts for 3,861. 2,910 are within a factor 10 of this equity.See the whole sector
Company data · Crossroads Bank
Identification
Legal formPrivate limited company
Founded06-03-2016
Fiscal year end31-12
Activities, NACEBEL
47730Retail sale of pharmaceutical products
Sources
Crossroads Bank for EnterprisesNational Bank · 9 filingsAddress and cadastre registers
Data from official sources, last processed on 19-09-2026. Scores and ratios are computed by Checked and are not a credit decision.
Contact details
3 entriesE-mail:pharmaciewalcourt@gmail.com
Phone:071611476
Fax:071611476